DrugPatentWatch Database Preview
Hetero Labs Ltd Iii Company Profile
What is the competitive landscape for HETERO LABS LTD III, and what generic and branded alternatives to HETERO LABS LTD III drugs are available?
HETERO LABS LTD III has thirty-six approved drugs.
There are four tentative approvals on HETERO LABS LTD III drugs.
Summary for Hetero Labs Ltd Iii
| US Patents: | 0 |
| Tradenames: | 31 |
| Ingredients: | 30 |
| NDAs: | 36 |
Drugs and US Patents for Hetero Labs Ltd Iii
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hetero Labs Ltd Iii | STAVUDINE | stavudine | CAPSULE;ORAL | 078957-004 | Dec 29, 2008 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Hetero Labs Ltd Iii | EFAVIRENZ | efavirenz | TABLET;ORAL | 078886-001 | Apr 27, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Hetero Labs Ltd Iii | STAVUDINE | stavudine | CAPSULE;ORAL | 078957-002 | Dec 29, 2008 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Hetero Labs Ltd Iii | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 210692-001 | Oct 11, 2018 | AB | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
